These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 21813533)

  • 21. Novel immunomodulatory compounds in multiple myeloma.
    Saini N; Mahindra A
    Expert Opin Investig Drugs; 2013 Feb; 22(2):207-15. PubMed ID: 23265189
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The European medicines agency review of pomalidomide in combination with low-dose dexamethasone for the treatment of adult patients with multiple myeloma: summary of the scientific assessment of the committee for medicinal products for human use.
    Hanaizi Z; Flores B; Hemmings R; Camarero J; Sancho-Lopez A; Salmonson T; Gisselbrecht C; Laane E; Pignatti F
    Oncologist; 2015 Mar; 20(3):329-34. PubMed ID: 25673103
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Pomalidomide for multiple myeloma].
    Fouquet G; Macro M; Decaux O; Fohrer C; Guidez S; Demarquette H; Le Grand C; Prodhomme C; Renaud L; Bories C; Herbaux C; Karlin L; Roussel M; Benboubker L; Hulin C; Arnulf B; Leleu X
    Rev Med Interne; 2015 Sep; 36(9):613-8. PubMed ID: 26257103
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Lenalidomide-induced acute lung injury in case of multiple myeloma.
    Danbara M; Tadera N; Togano T; Katayama T; Aoki T; Miyazaki K; Higashihara M
    Int J Clin Pharmacol Ther; 2013 Jun; 51(6):513-6. PubMed ID: 23557868
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Lenalidomide in multiple myeloma: Current status and future potential.
    Quach H; Kalff A; Spencer A
    Am J Hematol; 2012 Dec; 87(12):1089-95. PubMed ID: 22641420
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Carfilzomib and pomalidomide: recent advances in the treatment of multiple myeloma.
    Highsmith KN; Chen SE; Horowitz S
    Pharmacotherapy; 2014 Sep; 34(9):927-40. PubMed ID: 25044413
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Pomalidomide for patients with multiple myeloma.
    Gras J
    Drugs Today (Barc); 2013 Sep; 49(9):555-62. PubMed ID: 24086951
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Neutrophilic dermatosis complicating lenalidomide therapy.
    Thieu KP; Rosenbach M; Xu X; Kist JM
    J Am Acad Dermatol; 2009 Oct; 61(4):709-10. PubMed ID: 19577327
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Drug-induced interstitial pneumonitis due to low-dose lenalidomide.
    Kunimasa K; Ueda T; Arita M; Maeda T; Hotta M; Ishida T
    Intern Med; 2012; 51(9):1081-5. PubMed ID: 22576392
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Pomalidomide-Induced Pulmonary Toxicity in Multiple Myeloma.
    Modi D; Mamdani H; Vettese T
    Am J Med Sci; 2015 Sep; 350(3):241-2. PubMed ID: 26200951
    [No Abstract]   [Full Text] [Related]  

  • 31. Evaluating the use of appropriate anticoagulation with lenalidomide and pomalidomide in patients with multiple myeloma.
    Anderson SM; Beck B; Sterud S; Lockhorst R; Ngorsuraches S
    J Oncol Pharm Pract; 2019 Jun; 25(4):806-812. PubMed ID: 29486638
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Pomalidomide-induced lung injury: A case report.
    Vivien A; Ancel J; Godet S; Dury S; Perotin JM; Deslee G; Launois C
    Medicine (Baltimore); 2023 Jan; 102(2):e32473. PubMed ID: 36637962
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Cytogenetics and long-term survival of patients with refractory or relapsed and refractory multiple myeloma treated with pomalidomide and low-dose dexamethasone.
    Dimopoulos MA; Weisel KC; Song KW; Delforge M; Karlin L; Goldschmidt H; Moreau P; Banos A; Oriol A; Garderet L; Cavo M; Ivanova V; Alegre A; Martinez-Lopez J; Chen C; Spencer A; Knop S; Bahlis NJ; Renner C; Yu X; Hong K; Sternas L; Jacques C; Zaki MH; San Miguel JF
    Haematologica; 2015 Oct; 100(10):1327-33. PubMed ID: 26250580
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Thalidomide-analogue biology: immunological, molecular and epigenetic targets in cancer therapy.
    Shortt J; Hsu AK; Johnstone RW
    Oncogene; 2013 Sep; 32(36):4191-202. PubMed ID: 23318436
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Pomalidomide for multiple myeloma.
    Fouquet G; Bories C; Guidez S; Renaud L; Herbaux C; Javed S; Facon T; Leleu X
    Expert Rev Hematol; 2014 Dec; 7(6):719-31. PubMed ID: 25265911
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Cost effectiveness of pomalidomide in patients with relapsed and refractory multiple myeloma in Sweden.
    Borg S; Nahi H; Hansson M; Lee D; Elvidge J; Persson U
    Acta Oncol; 2016 May; 55(5):554-60. PubMed ID: 27123742
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Pomalidomide therapy for myeloma.
    Schey S; Ramasamy K
    Expert Opin Investig Drugs; 2011 May; 20(5):691-700. PubMed ID: 21413906
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Interstitial pneumonitis associated with the immunomodulatory drugs thalidomide and lenalidomide.
    Iino M
    Int J Hematol; 2012 Feb; 95(2):223-4. PubMed ID: 22198829
    [No Abstract]   [Full Text] [Related]  

  • 39. The safety of pomalidomide for the treatment of multiple myeloma.
    Jones JR; Pawlyn C; Davies FE; Morgan GJ
    Expert Opin Drug Saf; 2016; 15(4):535-47. PubMed ID: 26913560
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Treatment-related adverse events in patients with relapsed/refractory multiple myeloma.
    Vij R
    Oncology (Williston Park); 2011 Nov; 25 Suppl 2():45-55. PubMed ID: 25188481
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.